|Bid||5.73 x 800|
|Ask||5.85 x 2200|
|Day's Range||5.63 - 6.10|
|52 Week Range||3.56 - 16.47|
|Beta (5Y Monthly)||4.57|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $5.70, marking a -0.35% move from the previous day.
As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
As the end of 2019 approaches, the cannabis industry and related parties seek to end a harsh year on a positive note. On the bright side, the U.S. House and Senate agreed to include a few marijuana, hemp and CBD-related provisions in federal spending bills, the EPA came out with a list of approved pesticides for hemp growers in 2020, New Jersey decided to put an adult-use marijuana legalization referendum in next year’s ballot, and South Dakota’s Secretary of State Steve Barnett said the petition submitted for an initiated measure on medical marijuana legalization was validated and filed by his office Thursday. Back to federal spending, lawmakers agreed on a $1.4 trillion government-wide 2020 spending package containing two spending bills, one of which touches on hemp-derived CBD and provides the FDA and USDA with $2 million for research, policy evaluation, market surveillance and issuance of an enforcement discretion policy.
The Zacks Analyst Blog Highlights: Uber, AES, CIRCOR International, Edwards Lifesciences and Zynerba Pharmaceuticals
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) shares ended Monday's session nearly 15% higher after Canaccord Genuity said the stock's mid-September sell-off was unjustified. The Analyst Sumant Kulkarni ...
Zynerba (ZYNE) has been issued a US Patent titled "Treatment of Fragile X Syndrome with Cannabidiol", notes biotechnology specialist John McCamant, editor of The Medical Technology Stock Letter.
Armando Anido became the CEO of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) in 2014. This analysis aims first to...
In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $7.44, marking a -0.53% move from the previous day.
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the third quarter driven by clinical studies on its lead pipeline candidate, Zygel.
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
The first half of 2020 will be crucial for Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE). The company is set to announce results from two trials of its so-far promising Zygel synthetic CBD transdermal gel, which it’s hoping will be used to treat childhood seizures and socio-psychological disorders in children. The company has already reported some positive topline results from a Phase 2 clinical trial of Zygel for children with rare developmental and epileptic encephalopathies, or DEE, disorders.
Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.
I've been keeping an eye on Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) because I'm attracted to its fundamentals...